, Volume 70, Issue 6, pp 691-732
Date: 17 Sep 2012

Rabbit Antithymocyte Globulin (Thymoglobulin®)

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The more than 25 years of clinical experience with rabbit antithymocyte globulin (rATG), specifically Thymoglobulin®, has transformed immuno-suppression in solid organ transplantation and haematology. The utility of rATG has evolved from the treatment of allograft rejection and graft-versus-host disease to the prevention of various complications that limit the success of solid organ and stem cell transplantation. Today, rATG is being successfully incorporated into novel therapeutic regimens that seek to reduce overall toxicity and improve long-term outcomes. Clinical trials have demonstrated the efficacy and safety of rATG in recipients of various types of solid organ allografts, recipients of allogeneic stem cell transplants who are conditioned with both conventional and nonconventional regimens, and patients with aplastic anaemia. Over time, clinicians have learnt how to better balance the benefits and risks associated with rATG. Advances in the understanding of the multifaceted mechanism of action will guide research into new therapeutic areas and future applications.